Lisa Miller | Authors


Debating the True Benefit of Adjuvant TKIs in High-Risk RCC

September 21, 2017

Adjuvant therapy with TKIs for patients with high-risk renal cell carcinoma who have undergone a nephrectomy may be supported by level IIa evidence from the National Comprehensive Cancer Network guidelines, yet this approach is still controversial, with many physicians believing that there are not yet enough data in support of its use.

Expert Sees Molecular Genetics Increasingly Integrated into Clinical Decision Making in MPNs

September 16, 2017

Advancements made in the field of molecular genetics for patients with myeloproliferative neoplasms may be increasingly incorporated into treatment decisions, according to a presentation by Ann Mullally, MD, during the 2017 SOHO Annual Meeting.

Improving Upon Exciting Radionuclide Therapy in Neuroendocrine Tumors

August 18, 2017

There is a great deal of excitement in the oncology field over the use of peptide receptor radionuclide therapy with lutetium-177 (177Lu)-octreotate (177 Lu-Dotatate, Lutathera) for the treatment of patients with neuroendocrine tumors. The treatment is being explored in potential combinations with other modalities, including with systemic treatment with PARP inhibitors, in this patient population.